Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258873 | 1.00 | OPRD1 (0.49) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL21462327 | 1.00 | OPRD1 (0.49) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL30034009 | 0.97 | OPRD1 (0.47) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL28665306 | 0.97 | OPRD1 (0.48) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL30366864 | 0.97 | OPRD1 (0.48) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL29565875 | 0.90 | KMT2A (0.54) | OPRD1KMT2AF2ACEALDH1A1 | |
| SCHEMBL28559438 | 0.90 | F2 (0.46) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL29591617 | 0.88 | OPRD1 (0.44) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL24378516 | 0.87 | OPRD1 (0.48) | OPRD1PREPKMT2AF2EPHX2 | |
| SCHEMBL29731400 | 0.87 | OPRD1 (0.48) | OPRD1PREPKMT2AF2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119709803-A | Enzymolysis preparation process of albumin oligopeptide | 湖北健肽生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119019488-A | Preparation method of chiral Fmoc-Gly-L-Pro-OH dipeptide | 苏州正济医药研究有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118546199-A | Preparation method of prostate cancer targeted fluorescent contrast agent, reagent and application of contrast agent and reagent | 新斗生物科技(苏州)有限公司 | 2024-08-27 | — | — | CN | claimed |
| CN-116813740-A | Solid phase synthesis method of cono anti-wrinkle agent | 瑞博(苏州)制药有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-114702546-B | Production process of tripeptide-29 | 山东济肽生物科技有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-114702546-A | Production process of tripeptide-29 | 山东济肽生物科技有限公司 | 2022-07-05 | — | — | CN | claimed |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| CN-121609747-A | Method for preparing Fmoc-Gly-Pro-OH | 常州吉恩药业有限公司 | 2026-03-06 | — | — | CN | disclosed |
| CN-121609747-A | Method for preparing Fmoc-Gly-Pro-OH | 常州吉恩药业有限公司 | 2026-03-06 | — | — | CN | disclosed |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | CARMOT THERAPEUTICS INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3774838-B9 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-3774838-B2 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-3774838-B1 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-08-10 | — | — | EP | disclosed |
| CN-114702546-A | Production process of tripeptide-29 | 山东济肽生物科技有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114702546-A | Production process of tripeptide-29 | 山东济肽生物科技有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2022087243-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-111499719-B | Method for synthesizing pramlintide | 杭州固拓生物科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | OPRD1 4664/4885PREP 429/4885KMT2A 1644/4885 |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | FOLH1, TGM2, SLC3A2 | OPRD1 4819/4885PREP 339/4885KMT2A 1200/4885 |
| US-20220162323-A1 | ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF | FGFR2, FGFR3, FGFR1 | OPRD1 4489/4885PREP 3276/4885KMT2A 1825/4885 |
| US-20260035406-A1 | SYNTHESIS OF GLP-1R/GIPR AGONISTS | GLP1R, GIPR, GRPR | OPRD1 802/4885PREP 1589/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.